Dr Katherine Forsey leads CMTA’s Strategy To Accelerate Research (CMTA-STAR), driving a global agenda to develop treatments for CMT. She oversees more than 50 active research projects, coordinates the CMTA-STAR Advisory Board, and serves as a key contact for biotech, pharma, and academic researchers. She also curates the Patients as Partners in Research platform, ensuring the CMT community remains at the center of treatment development. A PhD-trained research biologist, Katherine studied at the University of York, the University of Cambridge, and the Czech Veterinary Research Institute, and spent time in industry with Syngenta. Before joining CMTA in 2022, she held senior roles across science, education, and industry and ran a successful consultancy bridging science and real-world impact. Based in Yorkshire, England, Katherine helps expand CMTA’s global reach.